The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs by $7.3 billion over six years.
The "Big 3" PBMs also separately generated an estimated $1.4 billion of income from spread pricing, FTC finds.
The National Association of Chain Drug Stores is praising the Federal Trade Commission's (FTC) unanimous, 5-0, vote on Monday to release the second interim staff report on the FTC's study of big ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback